A Multi-center, Randomized, Double Blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Moderate-to-severe Atopic Dermatitis.

This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.

开始日期2026-01-30

申办/合作机构

上海长森药业有限公司

[+1]

JPRN-UMIN000059834

/ SuspendedN/AIIT

A Study on Pulmonary Function Using a Smartphone Application - A Study on Pulmonary Function Using a Smartphone Application

开始日期2025-11-21

申办/合作机构

Micron, Inc.

NCT06666335

/ Not yet recruiting临床4期

A Prospective, Open-label, Single Arm, Multicenter, Post-authorization Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Colchicine-resistant Familial Mediterranean Fever (FMF)

The purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with colchicine-resistand Familial Mediterranian Fever (FMF). The study consists of up to one month screening, to see if a patient is suitable to the study, 6 months of treatment with anakinra and one month safety follow up after last dose of anakinra. In total 3 patients, male and female from 2 years of age (minimum 10kg weight), will be enrolled to the study.

开始日期2025-09-01

申办/合作机构

Swedish Orphan Biovitrum AB

[+1]

100 项与 Hangzhou Tigermed Consulting Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Hangzhou Tigermed Consulting Co., Ltd. 相关的专利（医药）

登录后查看更多信息

项与 Hangzhou Tigermed Consulting Co., Ltd. 相关的文献（医药）

2026-04-01·CHEMISTRY AND PHYSICS OF LIPIDS

Lipid-based nanocarriers for antiviral drug delivery: A review of the advances, manufacturing technologies, therapeutic mechanisms, and clinical applications

Review

作者: Oswal, Krishil ; Maithania, Heena ; Varghese, Ryan ; Tiwary, Pooja

BACKGROUND:

The persistent global burden of viral infections, compounded by the emergence of resistance and suboptimal therapeutic efficacy, underscores the urgency for innovative treatment strategies. Recent viral outbreaks such as COVID-19, Human metapneumovirus (HMPV), Zika, Ebola, Nipah, and various influenza viral strains have highlighted the limitations of conventional antivirals. This necessitates the need for targeted, adaptable, and innovative drug delivery platforms. In light of this, LNCs have emerged as versatile systems capable of enhancing drug stability, biodistribution, and cellular uptake. With their tunable architecture and ability to encapsulate diverse antiviral agents, these nanocarriers offer a promising avenue to overcome pharmacological barriers, improve therapeutic efficacy, and enable effective intervention against both established and emerging viral pathogens.

METHOD:

To gather supporting evidence, publications were identified on Google Scholar, PubMed, and ScienceDirect with specific search terms such as "antivirals", "drug loading", "encapsulation efficiency", "lipid nanocarriers", "liposomes", "solid lipid nanoparticles (SLNs)", "nanostructured lipid carriers (NLCs)", "cubosomes", "virus", "viral disease", and "resistance". We did not impose any restrictions on the publication date during the selection of papers. However, it is imperative to highlight that the initial reports containing specified keywords began publication in 1964; it is noteworthy that a majority of these publications were 2000 or beyond.

CONCLUSION:

LNCs, including SLNs, NLCs, liposomes, and cubosomes, etc, demonstrated improved antiviral efficacy by enhancing drug stability, targeted delivery, and bioavailability. Several formulations showed superior pharmacokinetics and reduced toxicity compared to conventional therapies. Additionally, in vivo studies supported enhanced lymphatic uptake and therapeutic outcomes across multiple viral models. Despite notable progress, challenges in scalability, stability, and regulatory compliance limit their clinical translation. Hence, techniques such as microfluidics and other continuous manufacturing approaches improve reproducibility and process control. Moreover, artificial intelligence is revolutionizing LNC development by enabling rapid optimization, in silico prediction of pharmacokinetics, and real-time quality monitoring. Incorporating AI-enabled quality-by-design frameworks with state-of-the-art analytics may streamline regulatory approval. Moving forward, translating LNC technologies from bench to bedside will require scalable production methods, standardized characterization, and regulatory alignment.

2025-08-18·Bioanalysis

Bioanalysis for PK for antibody drug conjugates using ligand binding assay–challenges and bioanalytical strategies

Review

作者: Liu, Xiaonan ; Xu, Tao ; Zhang, Nan ; Lin, John (Zhongping)

Antibody-drug conjugates (ADCs) represent a rapidly advancing class of biotherapeutics for oncology and immunological indications. Comprehensive pharmacokinetic (PK) characterization is critical for assessing ADCs efficacy, safety, and overall therapeutic performance. Ligand binding assays (LBAs) are widely employed in both academic and industrial settings for the quantitative and semi-quantitative analysis of biologics. These assays rely on specific molecular interactions - commonly between antigens and antibodies or ligands and receptors - and offer high sensitivity, robustness, and cost-efficiency. In ADC bioanalysis, LBAs are utilized to quantify multiple types of analytes, including total antibody and antibody-drug conjugate. However, the development of LBA methods for ADCs is challenged by the structural heterogeneity of these molecules, analyte instability, and the need for high selectivity and sensitivity. This review summarizes the application of LBAs in ADC PK studies, outlines common methodological challenges, and discusses strategic considerations for assay development to ensure accurate and reliable bioanalytical measurements.

2025-08-01·TOXICOLOGY IN VITRO

In vitro metabolic clearance of malathion in rats and humans

Article

作者: Shen, Li ; Kassahun, Kelem ; Nallani, Gopinath ; Reiss, Rick ; Whatling, Paul ; Chandrasekaran, Appavu

In vitro intrinsic clearance of malathion was determined in adult and juvenile rat and human liver microsomes. Due to rapid elimination with no detectable levels of the parent, clearance rates of malathion were calculated from formation kinetics of its metabolites: malathion monocarboxylic acid (MMCA) and malaoxon. To correlate in vitro data to in vivo exposure, pharmacokinetics (PK) study was performed in adult rats following a single i.v. (10 mg/kg bw) or oral dose (150 mg/kg bw). The in vitro kinetics data indicate that the metabolic clearance of malathion via formation of MMCA was at the same rate in adult and juvenile human liver microsomes (HLM), but in rat liver microsomes (RLM) the rate was about 10-fold higher in adults compared to juveniles. The rate of formation of malaoxon among the two species and age groups was within 3.5-fold difference. The formation kinetics of malaoxon represented <0.5 % of that observed for MMCA in both rats and humans. As seen in the in vitro results, following i.v. or oral dosing in rats, malathion was not detectable with MMCA being the major metabolite. The kinetics data from this study were useful for the development of a PBPK model for malathion.

2,849

项与 Hangzhou Tigermed Consulting Co., Ltd. 相关的新闻（医药）

19 小时之前

·同写意

立足中国、链接全球：诺和控股对乐纯生物的赋能协同实践

引进/卖出

19 小时之前

·同写意

博生吉医药荣膺2026福布斯中国行业发展领创者・领军企业

细胞疗法免疫疗法ASH会议

20 小时之前

·同写意

汇芯生物与深圳明鉴达成战略合作，共建生物医学新技术一站式服务平台

100 项与 Hangzhou Tigermed Consulting Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Hangzhou Tigermed Consulting Co., Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2026年03月21日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

阿伐可泮 ( C5AR1 )	抗中性粒细胞胞质抗体相关性血管炎更多	批准上市
蔗糖铁 ( Phosphates )	慢性肾病更多	批准上市
羧基麦芽糖铁	缺铁性贫血更多	批准上市
阿普昔腾坦 ( ETA x ETB )	难治性高血压更多	临床3期
OQL-011 ( sGC )	皮肤疾病更多	临床2期